Nvidia’s AI Ambitions In Medicine/Health Care Are Clear
Nvidia has announced deals with Johnson & Johnson and GE Healthcare for generative AI in surgery and medical imaging improvements at its 2024 GTC AI conference.
These developments highlight the importance of medicine to Nvidia’s non-tech sector revenue opportunities in the future.
AI can accelerate drug discovery and find potential uses for drugs that may not have been successful in their initial target disease. Drug development is a risky process that can take at least a decade and cost billions.
About 41% of biotech CEOs surveyed by EY in late 2023 are considering “concrete” ways generative AI could be used for their companies. Nvidia’s health care focus at the conference reflects its long-standing ambition to reduce costs for pharmaceutical companies beyond the drug development process.
(With inputs from Shikha Singh)
You need to login in order to Like
